BRD2 and colorectal carcinoma: Using IHC, we also demonstrated an increased staining response against Mannitou, a paucimannose-reactive antibody (32, 33), in FFPE TUM sections from a CRC patient (stage II) compared to matching NAT (Fig. 1G and Supplemental Fig. S1).